Edition:
United Kingdom

Profile: Autolus Therapeutics PLC (AUTL.OQ)

AUTL.OQ on NASDAQ Stock Exchange Global Select Market

22.01USD
9:00pm BST
Change (% chg)

$-0.58 (-2.57%)
Prev Close
$22.59
Open
$22.47
Day's High
$22.92
Day's Low
$21.90
Volume
21,899
Avg. Vol
17,281
52-wk High
$53.14
52-wk Low
$19.33

Autolus Therapeutics plc, formerly Autolus Therapeutics Limited, is a development-stage biopharmaceutical company. The company is engaged in developing programmed T-cell therapies for the treatment of cancer. The Company's clinical-stage product candidates target hematological cancers. Its products candidates include AUTO2, AUTO3, AUTO4, and AUTO6. AUTO2 is a dual-targeting programmed T-cell therapy for the treatment of relapsed or refractory multiple myeloma targeting B-cell Maturation Antigen and the transmembrane activator. AUTO3 is a T-cell therapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma and pediatric relapsed acute B lymphocytic leukemia. Its AUTO4 is a T-cell therapy for the treatment of peripheral T-cell lymphoma.

The AUTO1 is a CD19-targeting programmed T cell therapy designed to improve the safety profile of the CD19 binder while maintaining its anti-leukemia activity. AUTO1 has demonstrated this anti-leukemia activity in the absence of severe cytokine release syndrome, or CRS, in a Phase I trial of 11 patients with pediatric relapsed or refractory acute B lymphocytic leukemia, or pediatric ALL.

The AUTO2, which is a first dual-targeting programmed T cell therapy for the treatment of relapsed or refractory multiple myeloma targeting B-cell Maturation Antigen, or BCMA, and the transmembrane activator and CAML interactor, or TACI. The Company also initiated a Phase I/II clinical trial. The AUTO3 is a dual-targeting programmed T cell therapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma, or DLBCL, and pediatric ALL, independently targeting B-lymphocyte antigens CD19 and CD22. We initiated separate Phase I/II clinical trials of AUTO3 in DLBCL and in pediatric ALL. The AUTO4 is a programmed T cell therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1. The Company intends to initiate a Phase I/II clinical trial.

The AUTO6 is a programmed T cell therapy targeting GD2 in development for the treatment of neuroblastoma. A Phase I clinical trial with AUTO6 is being sponsored and conducted by Cancer Research United Kingdom, or CRUK, and preliminary data has shown initial anti-tumor activity in this solid tumor indication. It also developing AUTO6 NG, incorporating additional programming modules designed to improve the efficacy, safety and persistence of AUTO6 and initiate a Phase I/II clinical trial of AUTO6 NG in 2020.

Company Address

Autolus Therapeutics PLC

White City, Forest House, 58 Woo
LONDON     W12 7RZ
P: +4420.38296230

Company Web Links